Thyroid Cancer Drugs Market Growth Outlook: Why Analysts Expect Continued Expansion
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Thyroid Cancer Drugs Market Forecast: Value Set To Climb From $1.47 Billion To $2.38 Billion
The market size for thyroid cancer drugs has expanded rapidly in recent years. It is projected to grow from $1.32 billion in 2025 to $1.47 billion in 2026, at a compound annual growth rate (CAGR) of 11.8%. The growth observed in the past can be attributed to the escalating incidence of thyroid cancer, the adoption of kinase inhibitors, advancements in cancer diagnostics, the expansion of oncology hospitals, and enhanced access to targeted therapies.
The thyroid cancer drugs market is anticipated to undergo substantial expansion over the next few years. It is projected to reach $2.39 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.8%. This growth during the forecast period is attributed to several factors, including the increasing availability of personalized oncology drugs, a rising incidence of advanced thyroid cancer, intensified clinical trial activity, the broadening scope of immunotherapy combinations, and elevated oncology healthcare spending. Furthermore, major trends for this period encompass the rising adoption of targeted multikinase therapies, increased use of combination drug regimens, a growing focus on advanced and refractory thyroid cancer, the expansion of precision oncology treatment approaches, and enhanced hospital-based thyroid cancer management.
Get A Free Sample Report With In-Depth Market Insights:
Thyroid Cancer Drugs Market Development Factors: What’s Supporting Demand?
The escalating occurrence of thyroid cancer is poised to drive the growth of the thyroid cancer drugs market in the coming years. Thyroid cancer involves malignant tumors developing in the thyroid gland, requiring prompt diagnosis and effective therapeutic intervention to prevent its progression and metastasis. The increase in thyroid cancer cases results from a combination of enhanced detection through more sensitive diagnostic procedures and a rise attributed to greater exposure to environmental factors. This growing prevalence of thyroid cancer bolsters the thyroid cancer drugs by stimulating demand for targeted therapies, immunotherapies, radiopharmaceuticals, and hormone-suppressing medications, which improve treatment outcomes and long-term survival. For instance, in September 2025, according to Cancer Research United Kingdom, a UK-based non-profit organization focused on cancer research and patient support, approximately 6,600 new cases of thyroid cancer are projected annually by 2038-2040, with incidence rates expected to rise by 27% from approximately 7.3 cases per 100,000 people per year in 2024-2026 to around 9.2 cases per 100,000. Therefore, the increasing incidences of thyroid cancer are propelling the expansion of the thyroid cancer drugs market.
Thyroid Cancer Drugs Market Segment Analysis: What Are The Core Market Categories?
The thyroid cancer drugs market covered in this report is segmented –
1) By Drug Type: Ipilimumab, Cabozantinib-S-Malate, Caprelsa (Vandetanib), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Nivolumab, Vandetanib, Other Drug Types
2) By Type: Radioiodine Ablation, Thyroid Stimulating Hormone (THS) Suppression, Chemotherapy, Targeted Multikinase Therapy, Other Types
3) By End Users: Hospitals, Oncology Clinics, Research Organizations, Other End-Users
Subsegments:
1) By Ipilimumab: Monotherapy Ipilimumab, Combination Therapy With Ipilimumab
2) By Cabozantinib-S-Malate: Single-Agent Cabozantinib, Combination Therapy With Cabozantinib
3) By Caprelsa (Vandetanib): Vandetanib For Medullary Thyroid Cancer (MTC), Combination Therapy With Vandetanib
4) By Doxorubicin Hydrochloride: Doxorubicin For Chemotherapy, Liposomal Doxorubicin
5) By Lenvatinib Mesylate: Lenvatinib For Differentiated Thyroid Cancer (DTC), Combination Therapy With Lenvatinib
6) By Nivolumab: Monotherapy Nivolumab, Combination Therapy With Nivolumab
7) By Vandetanib: Single-Agent Vandetanib, Combination Therapy With Vandetanib
8) By Other Drug Types: Sorafenib, Everolimus, Pembrolizumab
Thyroid Cancer Drugs Market Transformation Trends: What Innovations Are Driving Change?
Leading companies active in the thyroid cancer market are innovating products such as selpercatinib to enhance treatment possibilities and patient outcomes. Selpercatinib, available under the brand Retevmo, is a medicine used to treat various cancers associated with Rearranged During Transfection (RET) mutations, including advanced or metastatic medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer. For instance, in September 2024, Eli Lilly and Company, a US-based pharmaceutical firm, received approval for selpercatinib (Retevmo) from the Food and Drug Administration (FDA), a US-based federal body tasked with safeguarding public health, for the management of advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation. This authorization is valid for both adult and pediatric patients aged 2 years and older who require systemic therapy. This recent traditional approval represents a substantial improvement in treatment availability for patients with this specific variety of thyroid cancer.
Thyroid Cancer Drugs Market Top Companies Driving Competitive Growth
Major companies operating in the thyroid cancer drugs market are AbbVie Inc., AstraZeneca PLC, Bayer AG, Bristol Myers Squibb Company, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Eli Lilly and Company, Exelixis Inc., F. Hoffmann-La Roche Ltd, Ipsen Biopharmaceuticals Inc., Johnson & Johnson, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Amgen Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH
View The Full Thyroid Cancer Drugs Market Report:
Thyroid Cancer Drugs Market Regional Analysis And Leading Geography
North America was the largest region in the thyroid cancer drugs market in 2025. Middle East is expected to be the fastest-growing region in the thyroid cancer drugs market during the forecast period. The regions covered in the thyroid cancer drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
